logo
RFK Jr's vaccine panel to review long-approved jabs for children

RFK Jr's vaccine panel to review long-approved jabs for children

Yahoo6 hours ago

The new members of US Health Secretary Robert F Kennedy Jr's panel of vaccine advisers will review long-approved immunisation schedules for children and teens.
The seven members of the Advisory Committee on Immunization Practices (Acip) met for the first time on Wednesday, weeks after Kennedy ousted all 17 of their predecessors.
The Acip recommends who should be vaccinated and when to the US Centers for Disease Control and Prevention (CDC).
Ahead of the meeting, public health experts and politicians raised concerns about the qualifications of the new members - several of whom are vaccine critics.
The health secretary sparked uproar when he removed all 17 members of the ACIP on 9 June, and then hand-picked eight new members to serve on the panel - including one who dropped out hours before the first meeting.
Wednesday's meeting began with the new chair Dr Martin Kulldorff telling the panel that he was fired from his job as a professor at Harvard University because he refused to get a Covid-19 vaccine.
Dr Kulldorff also announced the panel would launch new working groups to examine child vaccination schedules and vaccines that were approved seven or more years ago.
He said it would be reviewed whether it was "wise" to give the hepatitis B vaccines to newborns, a shot proven safe and effective at preventing the infection that causes liver cancer.
Vaccine schedules for measles would also be reviewed, he said.
Examining vaccines licensed seven or more years ago raises concerns, because it suggests the process to approve them was flawed, said Bill Hanage, a professor of epidemiology at Harvard TH Chan School of Public Health.
"I cannot think of any rational reason you would look at that and think it to be the case," he said.
The panel was initially meant to vote on recommendations for shots against RSV, a respiratory virus that can be dangerous for infants, but that has been postponed.
On Thursday, the group is scheduled to hear a presentation on the use of thimerosal in vaccines given by Lyn Redwood, a former leader of Children's Health Defense, an anti-vaccine group Kennedy used to run.
Ms Redwood has been hired by the CDC to work in its vaccine safety office, according to the BBC's US partner CBS News.
The decision for the panel to discuss thimerosal, a mercury-based preservative that has not been used in most vaccines for decades, is perplexing, Dr Hanage said.
In the past, he said, Acip's members had a wide range of vaccine expertise and would scrutinise vaccine recommendations for months.
This time, Kennedy chose for the panel "people that are like him - people in the past who have shown an anti-vaccine bias", said Dr Paul Offit, a former Acip member and director of the Vaccine Education Center at Children's Hospital of Philadelphia.
One of the new Acip members was Dr Michael Ross, however he withdrew this week ahead of a review of members' financial holdings, the Department of Health and Human Services said.
Kennedy's panel choices have also sparked criticism from Republican Senator Bill Cassidy, a physician who was sceptical of voting to confirm Kennedy as health secretary because of his stances on vaccines.
In a post on X, Cassidy said the panel should not proceed with their meeting because of the group's small size and the lack of a CDC director in place to approve their recommendations.
"Although the appointees to ACIP have scientific credentials, many do not have significant experience studying microbiology, epidemiology or immunology," he wrote.
"In particular, some lack experience studying new technologies such as mRNA vaccines, and may even have a preconceived bias against them."
RFK Jr appoints new US vaccine advisers after sacking committee
RFK Jr sacks entire US vaccine committee

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Manhattan Mental Health Counseling launches Progress Pathways, a new initiative to track progress and growth in therapy
Manhattan Mental Health Counseling launches Progress Pathways, a new initiative to track progress and growth in therapy

Associated Press

timean hour ago

  • Associated Press

Manhattan Mental Health Counseling launches Progress Pathways, a new initiative to track progress and growth in therapy

Manhattan Mental Health Counseling (MMHC) launches Progress Pathways, an innovative new way for clients to track growth in therapy. New York, June 26, 2025 -- Manhattan Mental Health Counseling has launched Progress Pathways, a new initiative designed to help active clients mark their progress and stay motivated in therapy over time. Progress Pathways introduces a five-level framework tied to consistent therapy attendance and engagement. As clients continue to show up and work on themselves, they unlock messages, badges, and trophies. These milestones are designed to acknowledge commitment and dedication, spark reflection and encourage continued progress. The new scheme is a light structure that reinforces the often slow and steady nature of emotional growth. Steven Buchwald, managing director of Manhattan Mental Health Counseling, shared, 'We're here to help people move forward — with dignity, with agency, and with tools that last. Progress Pathways reinforces that therapy isn't just about showing up — it's about building something over time. This program turns that progress into something you can actually see and feel.' While not tailored to individual treatment plans, Progress Pathways helps clients stay oriented in their journey and recognize that forward motion is happening. The new program reflects the practice's commitment to practical, ethically grounded support that strengthens engagement. Progress Pathways is part of a growing movement to make therapy not only more accessible but also more meaningful. It is a motivational support program designed to complement, but not replace, personalized treatment plans. All treatment decisions remain the responsibility of each client's licensed therapist. The goal is to use Progress Pathways alongside individualized therapy plans to turn growth into visible, tangible, measurable wins, encouraging clients to celebrate milestones and achievements one step at a time and continue on their journey. By accessing the program, clients can unlock badges and trophies and monitor how close they are to their next milestone via progress bars. Each client can use the initiative like a transformation roadmap, which helps them get closer to their final destination. About Manhattan Mental Health Counseling Manhattan Mental Health Counseling is an established provider of online mental health services, which strives to make effective, personalized therapy accessible to all. Founded by Natalie Buchwald, LMHC, MMHC delivers mental health counseling across New York State and New Jersey. The mission is to empower individuals and build mental resilience to help clients live their lives with renewed energy, enthusiasm, strength, and purpose. MMHC has a dedicated team of experienced, licensed therapists. The recent launch of Progress Pathways marks an exciting milestone for MMHC, with clients now able to track growth by unlocking levels and gaining recognition of achievements and progress. A simple, effective roadmap, the program is designed to encourage continued commitment, inspire and motivate individuals to work towards the next milestone, and help them celebrate growth. Anyone who would like to learn more about Manhattan Mental Health Counseling is encouraged to make use of the following contact details: Contact Info: Name: Steven Buchwald Email: Send Email Organization: Manhattan Mental Health Counseling Address: 303 Fifth Avenue Suite 1108, New York, NY 10016 Phone: 212-960-8626 Website: Release ID: 89163189 In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.

Oppenheimer Raises TransMedics (TMDX) PT to $150 Following Key OrganOx Metra Label Update
Oppenheimer Raises TransMedics (TMDX) PT to $150 Following Key OrganOx Metra Label Update

Yahoo

timean hour ago

  • Yahoo

Oppenheimer Raises TransMedics (TMDX) PT to $150 Following Key OrganOx Metra Label Update

TransMedics Group Inc. (NASDAQ:TMDX) is one of the best mid cap growth stocks to invest in now. On June 17, Oppenheimer increased the price target for TransMedics to $150 from $130, while maintaining an Outperform rating on the shares. This adjustment came after the OrganOx Metra device had its air transport warning removed from its label on June 2. The OrganOx Metra device is a competitor in the organ preservation market. Despite mixed outcomes from field checks on the Metra device, OrganOx continues to receive positive feedback from the Organ Procurement Organization community. Oppenheimer expects that the OrganOx Metra device will likely gain market share in DCD/Donation after Circulatory Death liver transplants. This is attributed not necessarily to superior outcomes compared to TransMedics' technology, but rather to a perceived strained relationship between TransMedics and the OPOs. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. In Q1 2025, TransMedics achieved a record total revenue of $143.5 million, which showed a 48% year-over-year growth compared to $96.9 million in Q1 2024. Transplant services revenue specifically saw a 56% increase due to higher utilization of their OCS NOP/Organ Care System National Organ Preservation platform. TransMedics also raised its full-year 2025 revenue guidance to a range between $565 and $585 million, which represents a 30% growth at the midpoint. TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that transforms organ transplant therapy for end-stage organ failure patients internationally. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

CDC vaccine panel to review ingredient RFK Jr has targeted for removal
CDC vaccine panel to review ingredient RFK Jr has targeted for removal

Yahoo

timean hour ago

  • Yahoo

CDC vaccine panel to review ingredient RFK Jr has targeted for removal

A key vaccine advisory panel reconstituted by health secretary and vaccine skeptic Robert F Kennedy Jr is slated to discuss thimerosal-containing influenza vaccines in its first meeting – an ingredient which has been a fixation of anti-vaccine activists for decades. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) will hold two separate votes later this month: one on 'influenza vaccines' and one on influenza vaccines that contain thimerosal. Thimerosal is an ethylmercury preservative used in multi-dose vaccine vials to prevent fungi and bacteria growth. The preservative has been studied and deemed safe, but was nevertheless removed from all routine childhood vaccines in 2001 as a precaution. 'I was there when we went through this the first time,' said Dr Paul Offit, director of the vaccine education center and an attending physician in the division of infectious diseases at Children's Hospital of Philadelphia, about debates over the preservative in the early 2000s. Offit served on the ACIP panel in question from 1998 to 2003. He said the issue of thimerosal was vigorously debated and found safe then, prompting him to ask: 'What's the point?' In a short history of the thimerosal controversy published in the New England Journal of Medicine, Offit described how some parents became convinced thimerosal gave their children autism, resulting in thousands of autistic children receiving heavy metal chelation treatments each year. Studies have found no link between thimerosal and autism, according to the American Academy of Pediatrics. The National Vaccine Injury Compensation Program has also denied claims of a thimerosal-autism link. Kennedy, however, has written a book arguing against the use of thimerosal. Offit said the discussion of thimerosal appeared to geared to, 'accomplish [Kennedy's] goals of making vaccines less affordable, less accessible and more feared', he said. 'Here's what you do know – you do know RFK Jr is an anti-vaccine, science-denying conspiracy theorist. He is devoted to this, he is a zealot, there is no middle ground with him,' said Offit. 'He believes we have merely substituted infectious diseases for chronic diseases.' The panel's advisory recommendations are critical because they result in vaccine 'schedules'. These schedules are relied on by health insurers to determine which vaccines to cover and by clinicians who use them as an evidence-based guide on immunization – effectively giving the American public access to the medicines. Although the CDC does not always take the panel's advice, the CDC typically affirms the panel's decisions. However, the agency is currently without a leader, as Senate hearings have not yet been held for nominee and CDC career official Susan Monarez. As a result, Kennedy has signed off on some previous ACIP recommendations. Kennedy wrote a book on the preservative thimerosal in 2014 called Thimerosal: Let the Science Speak, in which he argues that 'there is a broad consensus among research scientists that thimerosal is a dangerous neurotoxin that should be immediately removed from medicines'. Kennedy said in the book he is 'pro-vaccine'. Until 9 June, the ACIP was an independent panel of 17 experts who served staggered terms and were rigorously vetted by career CDC staff. Kennedy broke with tradition when he fired the entire panel, claiming in a Wall Street Journal editorial that he was working to 'restore public trust in vaccines'. The same week, Kennedy appointed eight new members to the committee, including medical professionals with little vaccine expertise and known vaccine skeptics. A wide spectrum of groups criticized the decision, from MomsRising, who said they were 'alarmed and disgusted', to major doctors' groups such as the American Academy of Pediatrics, to public health leaders who described Kennedy's actions as 'a coup,' to the former members of the committee, who warned the independent panel was at 'a crossroads'. The group is scheduled to meet the last week of June. Prior to Kennedy's changes, they had been expected to discuss reducing the number of shots needed for human papilloma virus (HPV) and a meningococcal vaccine. On Wednesday, the panel released a draft agenda for its upcoming meeting. A wide range of vaccines will be discussed – including those against influenza; the tropical disease chikungunya; the measles, mumps, rubella and varicella (chickenpox) vaccine; anthrax; Covid and respiratory syncytial virus (RSV). The agenda scheduled a vote on recommendations for flu vaccines, including the multidose versions that still contain thimerosal. These vaccines are used only in adolescents and adults. The panel is also scheduled to vote on recommendations for maternal and pediatric versions of the respiratory syncytial virus (RSV). Notably, despite Kennedy's repeated pledges of 'radical transparency', the draft agenda does not include the names of many speakers, which are listed as 'TBD' (to be determined) for instance on 'Covid-19 safety update'. New ACIP members have not been added to a conflict of interest tracker for ACIP members developed by the Trump administration. A spokesperson for HHS said the new members ethics agreements 'will be made public' before they start work with the committee. In addition to the new draft agenda, there have also been changes to the committee's meeting times not reflected in the Federal Register, according to Politico. The group will meet for two days instead of three, and there does not appear to be a vote scheduled on Covid vaccines.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store